VolitionRx Limited (NYSE:VNRX) Director Guy Archibald Innes Acquires 78,125 Shares

Key Points

• Guy Archibald Innes, a director of VolitionRx Limited, purchased 78,125 shares at an average price of $0.64, increasing his total ownership by 8.79% to 966,814 shares.
• VolitionRx's stock saw a 1.6% increase to $0.65, with a total volume of 167,946 shares traded, highlighting investor interest.
• Wall Street analysts maintain a Moderate Buy rating on VolitionRx, with target prices ranging from $2.50 to $5.00, indicating positive sentiment toward the company's potential growth.

VolitionRx Limited (NYSE:VNRX - Get Free Report) Director Guy Archibald Innes acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $0.64 per share, with a total value of $50,000.00. Following the purchase, the director owned 966,814 shares in the company, valued at approximately $618,760.96. This represents a 8.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Guy Archibald Innes also recently made the following trade(s):

• On Tuesday, June 3rd, Guy Archibald Innes bought 20,000 shares of VolitionRx stock. The shares were purchased at an average price of $0.54 per share, with a total value of $10,800.00.

VolitionRx Stock Performance

VNRX traded down $0.01 during trading on Friday, reaching $0.63. 13,289 shares of the stock were exchanged, compared to its average volume of 195,028. The stock has a market cap of $65.51 million, a P/E ratio of -1.74 and a beta of 1.26. VolitionRx Limited has a twelve month low of $0.40 and a twelve month high of $0.94. The stock's 50 day moving average price is $0.69 and its two-hundred day moving average price is $0.59.

Hedge Funds Weigh In On VolitionRx

Several hedge funds have recently bought and sold shares of VNRX. Millennium Management LLC bought a new stake in shares of VolitionRx in the fourth quarter worth $36,000. Northern Trust Corp boosted its holdings in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. grew its holdings in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the period. Two Sigma Securities LLC bought a new stake in VolitionRx in the fourth quarter valued at $29,000. Finally, Blair William & Co. IL acquired a new stake in shares of VolitionRx in the 2nd quarter valued at about $30,000. 8.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on VNRX shares. D. Boral Capital reiterated a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research report on Thursday, July 17th. Wall Street Zen started coverage on shares of VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating for the company. Finally, Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price for the company in a research report on Tuesday, June 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.